ClinicalTrials.gg
RecruitingNCT06133322BLESSEDUpdated Oct 1, 2026

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

An interventional study of Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline in Hypertension, sponsored by Tulane University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Tulane University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 1, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Hypertension by Tulane University — 2 open to participants now, 7 under way, none of them phase 3. Hypertension · Tulane University.

Planned enrollment
8th of 15
1,176 · median 1,176
Started
2023
with 2 others
No phase
13 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Hypertension by Tulane University, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 15th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 17 studies in Hypertension by Tulane University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypertension by Tulane University, or all of them as a file.
02

Study summary

The burden of hypertension and related cardiovascular diseases, stroke, and end-stage kidney disease is disproportionately high in Black populations, especially in the South. The Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial aims to test the effectiveness, implementation, and sustainability of a community health worker (CHW)-led multifaceted intervention compared to enhanced usual care for hypertension control in Black communities. In the BLESSED trial, the investigators plan to recruit 1,176 adults with hypertension (approximately 28 per church) from 42 predominantly Black churches in the Greater New Orleans area. The multifaceted intervention will last for 18 months, followed by a post-intervention follow-up visit at 24 months. The BLESSED trial aims to generate evidence regarding the effectiveness, implementation, and sustainability of this CHW-led church-based multifaceted intervention in eliminating hypertension disparities in the United States (US) general population.

Read the detailed description

Louisiana residents, especially African Americans, bear a disproportionately high burden of hypertension and cardiovascular disease (CVD). In the Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) cluster randomized trial, the investigators will compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2017 American College of Cardiology (ACC) and the American Heart Association (AHA) hypertension clinical guidelines on implementation and clinical effectiveness outcomes in predominantly Black community members over 18 months. The BLESSED study utilizes an effectiveness-implementation hybrid design to: (1). test the effectiveness of a CHW-led church-based multifaceted implementation strategy for reducing estimated CVD risk over 18 months among African American church community members at high risk for CVD, and (2). assess the implementation outcomes (acceptability, adaptation, adoption, feasibility, fidelity, penetrance, cost-effectiveness, and sustainability) simultaneously. The Exploration, Preparation, Implementation, Sustainment (EPIS) framework has guided the development and evaluation of the multifaceted implementation strategy, which includes CHW-led health coaching on lifestyle changes and medication adherence; healthcare delivery in community; church-based exercise and weight loss programs; self-monitoring of blood pressure (BP); and provider education and engagement. The CHW-led church-based intervention will provide strong social support and tackle multiple social determinants of CVD disparities. The primary clinical effectiveness outcome is the difference in mean change of systolic blood pressure (SBP) from baseline to 18 months between intervention and control groups. The primary implementation outcome is a fidelity summary score for key implementation strategy components to the CHW-led church-based multifaceted implementation strategy assessed at the participant levels. This study has 90% statistical power to detect group differences in mean SBP change of 5.8 mm Hg over 18 months using a 2-sided significance level of 0.05. The investigators will recruit 1,176 participants (28 per church) who are aged ≥18 years with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg, and randomly assign 21 churches to intervention and 21 to control; the investigators will implement the multifaceted intervention program; the investigators will follow-up participants and collect data on effectiveness and implementation outcomes at 6, 12, and 18 months; the investigators will evaluate the sustainability of the intervention at 6 months post-intervention; and the investigators will perform intention-to-treat analyses and disseminate and scale-up the proven-effective implementation strategy. The proposed study will generate evidence on the effectiveness, implementation, and sustainability of the multifaceted intervention aimed at eliminating CVD disparities in African American populations in the US.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • church-based
  • Black
  • African American
  • Community-based Intervention
  • health disparities
  • cardiovascular disease prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged ≥18 years
  2. Community members associated with the participating churches (church members and their families and friends)
  3. Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mm Hg
  4. Willing and able to participate in the intervention.
  5. Willing and able to sign written .

Exclusion criteria

Exclusion Criteria:

  1. Prior hospitalization in the last 3 months for chronic heart failure or heart attack
  2. Current diagnosis of cancer requiring chemotherapy or radiation therapy
  3. Stage-5 chronic kidney disease requiring chronic dialysis or transplant
  4. Pregnant or planning to become pregnant in the next 18 months
  5. Planning to move out of the Greater New Orleans area during the next year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,176 participants (estimated)

Study arms

  • Experimental
    Community health worker-led implementation strategy

    CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes.

    Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline

  • Experimental
    Group-based Education Strategy

    The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions.

    Behavioral: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline

Interventions

  • BehavioralBehavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline

    The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

06

What researchers measure

Primary outcomes

  1. Difference in mean change of systolic blood pressure

    Difference in mean change of systolic blood pressure from baseline to 18 months between intervention and control groups

    Time frame: Measured from baseline to 18 months

  2. Implementation fidelity summary score

    The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home blood pressure (BP) monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. The score ranged from zero to six with a higher score indicates greater fidelity.

    Time frame: Measured at 6, 12, and 18 months

Secondary outcomes

  1. Difference in the proportion of patients with controlled BP between intervention and control groups

    Difference in the proportion of patients with controlled BP (\<130/80 mm Hg) between intervention and control groups at 18 months

    Time frame: Measured from baseline to 18 months

  2. Difference in mean change of diastolic BP

    Difference in mean change of diastolic BP (DBP) from baseline to 18 months between intervention and control groups

    Time frame: Measured from baseline to 18 months

  3. Side effects of medications and adverse events

    Change in side effects of medications and adverse events from baseline to 18 months

    Time frame: Measured from baseline to 18 months

  4. Cost-effectiveness

    Cost-effectiveness assessed as incremental direct costs per additional percentage of hypertension control

    Time frame: Measured from baseline to 18 months

  5. Acceptability

    Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is acceptable (satisfactory). Measured by survey.

    Time frame: Measured from baseline to 18 months

  6. Adoption (Churches)

    % of churches adopting the intervention program

    Time frame: Measured from baseline to 18 months

  7. Adoption (Providers)

    % of invited providers attending training sessions

    Time frame: Measured from baseline to 18 months

  8. Appropriateness

    Percentage of participants, community health workers, providers, and church administrators who reply that the intervention is appropriate (good perceived fit). The outcome will be measured by survey question.

    Time frame: Measured from baseline to 18 months

  9. Feasibility to participant, community health worker, provider and churches

    Percentage of participants, community health worker, providers, and church administrators who reply that the intervention is feasible (actual fit, suitability). Measured by survey and study administrative data.

    Time frame: Measured from baseline to 18 months

  10. Exercise Session Fidelity (community health worker-led strategy group)

    Percentage of exercise sessions organized. Measured by study administrative data.

    Time frame: Measured at 6, 12, and 18 months

  11. Fidelity of Group Health Education Session

    Percentage of group health education sessions conducted out of health educated sessions planned per study protocol.

    Time frame: Measured at 6, 12, and 18 months

  12. Nutrition Education Session Fidelity (community health worker-led strategy group)

    Percentage of nutrition education sessions organized. Measured by study administrative data.

    Time frame: Measured at 6, 12, and 18 months

  13. Health Care Appointment Fidelity (community health worker-led strategy group)

    Percentage of health care visit appointments made. Measured by study administrative data.

    Time frame: Measured at 6, 12, and 18 months

  14. Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data. Reach (Participants)

    Percentage of enrolled participants receiving assigned intervention. Measured by study administrative data.

    Time frame: Measured at baseline, 6, 12, and 18 months

  15. Reach (Participants)

    The percentage of eligible/screened/contacted participants enrolled. Measured by study data, administrative data.

    Time frame: Measured at baseline

  16. Penetrance (Participants)

    Percentage of enrolled participants receiving assigned intervention. Measured by intervention monitoring data.

    Time frame: Measured at baseline, 6, 12, and 18 months

  17. Penetrance (Providers)

    Percentage of trained providers delivering protocol-based care. Measured by intervention monitoring data.

    Time frame: Measured at baseline, 6, 12, and 18 months

  18. Penetrance (educators)

    Percentage of trained CHWs or providers and health educators delivering health coaching. Measured by intervention monitoring data.

    Time frame: Measured at baseline, 6, 12, and 18 months

  19. Sustainability (Churches)

    Percentage of churches continuing the intervention program and individual components. Measured by 6-month post-intervention survey.

    Time frame: Measured at baseline, 6, 12, and 18 months

  20. Sustainability (Participants)

    Percentage of participants maintaining ideal cardiovascular health metrics, healthy lifestyle components, and adherence to medications. Measured by 6-month post-intervention survey and examination.

    Time frame: Measured at 24 months

  21. Sustainability Effectiveness Outcome: Differences in mean change of SBP and DBP

    Differences in mean change of SBP and DBP from baseline to 24 months (6 months post-intervention) between intervention and control groups

    Time frame: Measured at baseline and 24 months

  22. Sustainability Effectiveness Outcome: Difference in the proportion of patients with controlled BP

    Difference in the proportion of patients with controlled BP (\<130/80 mm Hg) between intervention and control groups at 24 months.

    Time frame: Measured at baseline and 24 months

  23. Sustainability of Fidelity

    A fidelity summary score for key implementation strategy components at 6 months post-intervention (24 months overall). The fidelity summary score is composed of the following key implementation strategy components: proportion of assigned health education sessions attended in all participants, proportion of assigned discussion sessions attended in all participants, proportion of recommended minutes of physical activity completed in all participants, proportion of days per week that fruits/vegetables are eaten as recommended in all participants, proportion of recommended home BP monitoring completed in patients with hypertension, proportion of required provider visits attended in all patients, and proportion of antihypertensive medications taken in patients with hypertension. Fidelity score ranges from zero to six with a higher score indicates greater fidelity.

    Time frame: Measured at 24 months

Other outcomes

  1. Change in quality of life

    The difference in QoL between the two arms over 18 months. QoL will be assessed using the SF-12 questionnaire. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Measured from baseline to 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Maroney K, Laurent J, Alvarado F, Gabor A, Bell C, Ferdinand K, He J, Mills KT. Systematic review and meta-analysis of church-based interventions to improve cardiovascular disease risk factors. Am J Med Sci. 2023 Sep;366(3):199-208. doi: 10.1016/j.amjms.2023.05.010. Epub 2023 May 25. PubMed 37244637 ↗
  • He J, Bundy JD, Geng S, Tian L, He H, Li X, Ferdinand KC, Anderson AH, Dorans KS, Vasan RS, Mills KT, Chen J. Social, Behavioral, and Metabolic Risk Factors and Racial Disparities in Cardiovascular Disease Mortality in U.S. Adults : An Observational Study. Ann Intern Med. 2023 Sep;176(9):1200-1208. doi: 10.7326/M23-0507. Epub 2023 Aug 15. PubMed 37579311 ↗
  • Bundy JD, Mills KT, He H, LaVeist TA, Ferdinand KC, Chen J, He J. Social determinants of health and premature death among adults in the USA from 1999 to 2018: a national cohort study. Lancet Public Health. 2023 Jun;8(6):e422-e431. doi: 10.1016/S2468-2667(23)00081-6. PubMed 37244672 ↗

Individual participant data

Plan to share: Yes — The study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository and will be implemented in a timely manner. The study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository - the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The datasets will be submitted to the NHLBI no later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first. The NHLBI will review the submitted data prior to release. These data will be free of identifiers that allow identification of individual research participants either directly or through "deductive disclosure." In addition, the investigators will offer, through a publicly accessible website, opportunities for outside investigators to collaborate using complete study data.

Supporting information: Study protocol, Statistical analysis plan

Time frame: No later than three years after the end of the final participant follow-up or two years after the main paper of the trial has been published, whichever comes first

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jun 2027, 43 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 43 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2027, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 15, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Jun 30, 2027was Aug 2026
CompletionEst.
Jun 30, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Jun 30, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Aug 31, 2026→Jun 30, 2027
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06133322
Lead sponsor
Tulane University
Responsible party
Jiang He, MD, PhD (Director Tulane University Translational Science Institute, Tulane University) — Principal investigator
First posted
Nov 15, 2023
Start date
Nov 1, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion